DelveInsight’s “Epigenetics Market Insights and Forecast – 2034” report delivers an in-depth understanding of the epigenomics market, covering product, technology, application, end-user, and geography-based trends across North America, Europe, Asia-Pacific, and the Rest of World.
Key Takeaways from the Epigenetics Market Report
- In January 2025, Tune Therapeutics raised USD 175 million to advance TUNE-401, an epigenetic-editing candidate designed to silence the hepatitis B epigenome.
- In January 2025, Chroma Medicine and Nvelop Therapeutics merged to form nChroma Bio, securing USD 75 million to advance an epigenetic-editing candidate for viral hepatitis.
- The epigenetics market size was estimated at USD 2.70 billion in 2025 and is projected to reach USD 8.30 billion by 2034, growing at a CAGR of 13.3% from 2026 to 2034.
- By product, the kits and reagents segment dominated the Epigenetics market with a 41% share in 2025, owing to their repeated consumption across DNA methylation, chromatin, and sequencing workflows.
- By technology, the DNA methylation segment led the market with a 48% share in 2025, reflecting its clinical validation in cancer biomarker discovery.
- By application, oncology dominated with a 60% share in 2025, supported by the rising global cancer burden and the maturation of methylation-based liquid biopsy.
- By end user, pharmaceutical and biotechnology companies accounted for the largest share at 44% in 2025, driven by heavy investment in epigenetics-driven drug discovery and companion diagnostics.
- North America led the global market with a 43% revenue share in 2025, anchored by strong United States epigenetics research funding and a dense concentration of leading tool providers.
- Asia-Pacific emerged as the fastest-growing region, with rising India epigenetics research activity contributing to regional momentum alongside China, Japan, South Korea, and Australia.
- The Epigenetics Companies such as Thermo Fisher Scientific, Illumina, Merck KGaA, QIAGEN, F. Hoffmann-La Roche, Danaher Corporation, Bio-Rad Laboratories, Revvity, New England Biolabs, and Active Motif, among others.
Epigenetics Market Segmentation
- Epigenetics Market by Product: Kits and Reagents, Enzymes, Instruments and Accessories, Software and Services
- Epigenetics Market by Technology: DNA Methylation, Histone Modification, Chromatin Structure and Accessibility, Non-Coding RNA Analysis
- Epigenetics Market by Application: Oncology, Immunology and Autoimmune Diseases, Developmental Biology, Cardiovascular and Metabolic Diseases
Epigenetics Emerging Therapies and Technologies
- TUNE-401: Tune Therapeutics TUNE-401 is a programmable epigenetic-editing candidate designed to silence the hepatitis B epigenome without altering the underlying DNA sequence, offering a potentially durable and reversible approach for chronic hepatitis B, and reflecting the growing pipeline of epigenetics drugs moving toward clinical application.
- CRMA-1001: nChroma Bio CRMA-1001 is an epigenetic-editing candidate for viral hepatitis, developed following the merger of Chroma Medicine and Nvelop Therapeutics, combining programmable gene-silencing platforms to accelerate development of next-generation epigenetic therapeutics.
Epigenetics Market Outlook
The epigenetics market encompasses the products, technologies, and services used to analyze and manipulate heritable, non-DNA-sequence changes in gene expression. Growth is anchored in the rising global cancer burden, the expansion of precision medicine, and rapid innovation across sequencing, single-cell, and epigenetic-editing platforms. Kits, reagents, and enzymes remain the primary revenue-generating consumables, supporting recurring, high-frequency demand from pharmaceutical companies, academic institutes, and clinical laboratories. Beyond oncology, applications are expanding into immunology, neurology, cardiovascular disease, and developmental biology, broadening the field’s addressable market. Meanwhile, the diagnostic technologies market built around methylation-based liquid biopsy is advancing non-invasive cancer detection, tissue-of-origin prediction, and recurrence monitoring, embedding epigenetics further into routine precision-oncology pipelines.
Scope of the Epigenetics Market Report
- Coverage- Global
- Study Period- 2023-2034
- Epigenetics Companies- Thermo Fisher Scientific, Illumina, Merck KGaA, QIAGEN, F. Hoffmann-La Roche, Danaher Corporation, Bio-Rad Laboratories, Revvity, New England Biolabs, and Active Motif, among others
- Epigenetics Therapeutic Assessment: Current epigenetic tools and emerging epigenetic-editing therapeutics
- Epigenetics Market Dynamics: Epigenetics Market drivers and Epigenetics Market barriers, including complexity, cost, and standardization gaps affecting the broader US diagnostic technologies and global testing landscape
Latest Reports offered by Delveinsight
acute kidney injury market | acute on chronic liver failure aclf market | acute pulmonary embolism market | advanced wound care market | alcoholic hepatitis market | amebiasis market | anal cancer market | antibody-mediated rejection market | automated external defibrillators market | bag3-related gene therapies market | biliary stents market | cancer vaccines market | capnography device market | cardiac rhythm management devices market | catheter stabilization devices market | cervical intraepithelial neoplasia market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk